Survival outcomes of radical surgery after induction chemoimmunotherapy in clinical stage IIIA–IIIB (N2) non-small cell lung cancer

作者：Pengfei Li, Xin Wang, Miqi Gu, Kaili Huang, Long Tian, Jue Li, Qiang Wu, T. Wang, Jintao He, Guowei Che, Qinghua Zhou · 发表于：Chinese Medical Journal · 年份：2025 · DOI：10.1097/cm9.0000000000003664 · 研究领域：Lung Cancer Diagnosis and Treatment、Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations

To the Editor: Neoadjuvant chemoimmunotherapy (NCIT) followed by surgery has been widely used for stage III patients with resectable tumors and limited mediastinal node (N2) involvement.[1–3] In clinical practice, patients typically undergo two to four cycles of induction chemoimmunotherapy (ICIT), after which they are re-evaluated through multidisciplinary team (MDT) discussions to assess the feasibility of surgical intervention.[4,5] Individuals who meet the surgical criteria could be scheduled for surgery. However, little is known about the impact of ICIT followed by radical surgery on stage IIIA–IIIB (N2) patients. Thus, we conducted a retrospective analysis of patients receiving ICIT followed by radical resection from two large-volume centers in China to explore the impact of ICIT on mid-/long-term survival in IIIA–IIIB (N2) NSCLC patients in the real world. This study was approved by the Institutional Review Boards of West China Hospital, Sichuan University (2024-674) and Sichuan Cancer Hospital (SCCHEC-02-2022-124). Informed consent was waived by the Ethical Committees. The detailed information on study design and analysis is presented in Supplementary Methods and Supplementary Figures 1 and 2, https://links.lww.com/CM9/C486. A total of 86 patients were included and more than half of the patients (55.81%) had stage IIIB (N2) disease, and the others had stage IIIA disease [Supplementary Table 1, https://links.lww.com/CM9/C486]. Fifty-six patients (65.12%) received two c...